Barbara W. Bodem

Director

Barbara W. Bodem is an independent director who joined our Board in January 2022 and is Chair of the Audit Committee. Ms. Bodem currently serves as Interim CFO of Dentsply Sirona, Inc. (Nasdaq: XRAY), a manufacturer of professional dental products and technologies, a position she has held since April 2022. Ms. Bodem served as the Senior Vice President and Chief Financial Officer at Hillrom, a global medical technology company, from 2018 until its acquisition by Baxter International Inc. (NYSE: BAX) in 2021. She previously served as the Senior Vice President of Finance at Mallinckrodt Pharmaceuticals, a pharmaceutical manufacturer, from 2015 to 2018. She has also served in senior finance roles for Hospira, Inc. and Eli Lilly & Company (NYSE: LLY).

Ms. Bodem currently serves on the board of directors of Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a clinical-stage precision oncology company, where she serves as Chair of the Audit Committee and as a member of the Compensation Committee and Enovis Corporation (NYSE: ENOV), a specialty medical technology business where she serves as a member of the Audit Committee. She received both her Bachelor of Science in Finance and MBA from Indiana University.

Financial Expert